Synribo and Breastfeeding
The manufacturer of Synribo (omacetaxine) recommends that women either avoid breastfeeding during treatment or not receive the drug. Although no studies have been done to determine if Synribo passes through breast milk or if it would harm a nursing infant, potentially dangerous side effects are possible, which may pose a risk to a baby whose mother uses the drug while breastfeeding.
Synribo™ (omacetaxine mepesuccinate) is a prescription chemotherapy medication used in the treatment of chronic myeloid leukemia, a rare disease of the blood and bone marrow. At this time, it is unknown whether Synribo passes through breast milk. The manufacturer recommends that women either breastfeed or receive treatment with this drug, but not both.
Synribo has not been studied in breastfeeding women. Therefore, it is unknown whether the drug passes through breast milk, or if it would harm a nursing child. It should be noted that medications are rarely studied in breastfeeding women, as doing so would usually expose an infant, who will not directly benefit from the drug, to possible risks.
Synribo is associated with potentially serious side effects. Because many medicines pass through breast milk, and because the risk for these side effects in a nursing infant cannot be completely ruled out at this time, it is probably safest to avoid breastfeeding while receiving the drug.
If your healthcare provider recommends breastfeeding during Synribo treatment, observe your child closely and report any potential side effects to your child's healthcare provider. Possible side effects may include but are not limited to: